Andere talen Evoke Pharma, Inc.

Aandelen

EVOK

US30049G2030

Beurs gesloten - Nasdaq Andere beurzen 22:30:01 16-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,47 ^USD	-1,09%		-11,32%	-55,25%

21/03	Evoke Pharma, Inc. kondigt bestuurswijzigingen aan vanaf 31 maart 2024	CI
21/03	Evoke Pharma, Inc. kondigt wijzigingen aan in de functie van Chief Executive Officer vanaf 31 maart 2024	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D’Onofrio to Chief Executive Officer	21/03
Evoke Pharma, Inc. Announces Board Changes as of March 31, 2024	21/03
Evoke Pharma, Inc. Announces Chief Executive Officer Changes as of March 31, 2024	21/03
Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results	14/03
Evoke Pharma, Inc. Provides Earnings Guidance for 2024	14/03
Evoke Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	14/03
Evoke Pharma to Report Fourth Quarter and Full Year 2023 Results on March 14, 2024	07/03
Evoke Pharma Announces Closing of $7.5 Million Public Offering	14/02
Evoke Pharma Prices Underwritten Public Offering	09/02
Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million	09/02
Revolutionizing gastroparesis treatment: Evoke Pharma's CEO talks game-changing nasal spray	30/11
Evoke Pharma Says FDA Lists Latest US Patent for Gimoti in Orange Book	27/11
Evoke Pharma Announces FDA Orange Book Listing of New GIMOTI Patent	27/11
Evoke Pharma : Failure to Satisfy Listing Rule - Form 8-K	22/11
Evoke Pharma - United States Patent and Trademark Office Grants another Formulation Patent Covering GIMOTI	15/11
United States Patent and Trademark Office (USPTO) Grants Another Formulation Patent Covering GIMOTI	14/11
Evoke Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
Evoke Pharma Reports Third Quarter 2023 Financial Results	09/11
Evoke Pharma and EVERSANA Unveil Cost Savings Real-World Data Demonstrating Meaningfully Reduced Healthcare Costs for Patients Using GIMOTI Over Oral Metoclopramide	01/11
Evoke Pharma, Inc. Provides Summary of Real-World Data on the Positive Impact of GIMOTI	01/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Evoke Pharma, Inc.

Aandelen

EVOK

US30049G2030

Andere talen

Filters